Novo Nordisk faces complex GLP-1 landscape as oral launch patterns diverge from injectables

Novo Nordisk's (NYSE:NVO) investor relations team presented at Deutsche Bank's European Champions Conference, with the broker maintaining its hold rating and DKK290 target price on the Danish pharma group. The key takeaway concerned the launch of Novo's oral semaglutide product, where the company confirmed that dose escalation patterns are not yet mirroring the trajectory seen with its injectable formulations.